Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of $2.6 million or $0.17 per unit, with cash available for distribution (CAD) at $2.8 million or $0.12 per unit [12][14] - The book value per unit as of December 31 was $11.70, with the closing unit price on March 18 at $5.87, reflecting a 50% discount to net book value [14][15] Business Line Data and Key Metrics Changes - The company is focused on exiting market rate multifamily joint venture equity investments while reallocating capital into tax-exempt Mortgage Revenue Bonds, which are expected to provide stable, tax-advantaged earnings [5][6] - The company currently has eight market rate multifamily JV equity investments that are either in lease-up or stabilized, with occupancy increasing for those in lease-up [8][10] Market Data and Key Metrics Changes - The fourth quarter of 2025 saw a recovery in the U.S. municipal bond market, with the high-grade index showing a 4.3% return for the year [26] - The 10-year MMD was at 2.76% and the 30-year MMD at 4.24% at year-end, with slight increases noted due to inflation uncertainty [27] Company Strategy and Development Direction - The company is repositioning its investment portfolio to focus on tax-exempt Mortgage Revenue Bonds, which are expected to yield stable returns compared to the uneven returns from joint venture equity investments [6][10] - The strategy aims to increase the proportion of tax-exempt income allocated to unitholders over the long term [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that it will take time to cycle capital out of market rate JV equity investments and into tax-exempt mortgage revenue bonds, but expects this transition to enhance recurring earnings in the long run [10][12] - The company is optimistic about the leasing trends as the spring leasing season approaches, indicating a potential recovery in occupancy rates [34][35] Other Important Information - The company reported unrestricted cash and cash equivalents of $39.5 million and approximately $49.2 million available on secured lines of credit as of December 31 [15][16] - The company has a significant amount of investments scheduled to mature in the first half of 2026, which will provide additional liquidity [15] Q&A Session Summary Question: Details on the $7 million losses and future expectations - Management explained that the losses were primarily due to four properties completing construction, leading to depreciation charges and low occupancy [31][32] Question: Insights on leasing trends for the upcoming season - Management noted that March to June is traditionally a strong leasing period and they are monitoring trends closely with property management firms [34][35] Question: Impact of foreclosures on financials - Management indicated that the initial basis in foreclosed properties would be around $112-$150 million, and they aim to recover the original basis through effective management [40][41] Question: Clarification on capital returns and contributions - The $4.5 million return of capital was related to refinancing two projects, and future contributions will depend on property tax payment timelines [44][47] Question: Confidence in management and investment strategy - Management addressed concerns about past investment strategies and emphasized their commitment to exiting JV investments and returning to core operations [52][53] Question: Valuation and market perception of book value - Management confirmed that they conduct quarterly impairment assessments on joint venture investments and are confident in the reported book value [58][59] Question: Future distribution rates and insider buying - Management stated that distribution rates will depend on the speed of capital recycling into more stable investments, and insider buying is subject to trading restrictions [78][81]

1 22 Forward-Looking Statements and Non-GAAP Financial Measures Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act, such as statements regarding expected cost savings, the optimization of our network through Network 2.0, the planned tax-free full separation of the FedEx Freight business into a new publicly traded company (the FedEx Freight Spin-Off), future financial targets, business strategies, management ...

Financial Data and Key Metrics Changes - In Q4 2025, gross revenue was EUR 6.3 million before deferrals, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [13] - For the full year 2025, gross revenue was EUR 11 million, leading to net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [14] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [13][14] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024 [13] - Total operating loss for the full year 2025 was EUR 83.5 million, up from EUR 58.8 million in 2024, reflecting increased commercialization activities [14][15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million in revenue generated from the first full quarter of launch [13][5] - 145 surgeons were trained across 125 high-volume hypoglossal nerve stimulation accounts in the U.S. [6] - 57 Value Analysis Committee approvals were received, with no rejections to date [6][7] Market Data and Key Metrics Changes - The U.S. market is the primary growth driver, with international markets contributing consistently, particularly in Germany, the UK, and the Middle East [12] - Medicare reimbursement for Genio has been consistent, representing 10% of the business, while commercial payers account for approximately 90% [9][10] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - Plans include expanding internal manufacturing to strengthen competitive position and improve gross margins [17] - The company is preparing for a PMA supplement submission based on 12-month ACCCESS study data, potentially leading to U.S. label expansion in early 2027 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, with expectations of 25% sequential growth in U.S. net revenue for Q1 and Q2 2026 [16] - The reimbursement environment is viewed as a normal maturation of an established therapy, with clarity on facility fees expected to support further adoption [11] Other Important Information - The company has a cash position of EUR 48 million as of December 31, 2025, with an expected cash burn of approximately EUR 20 million per quarter in the near term [15][30] - The introduction of new C-codes for AGNS by CMS is anticipated to facilitate billing for traditional Medicare patients [10] Q&A Session Summary Question: Status of Value Analysis Committee submissions and account activations - Management confirmed 120 VAC submissions with 57 approvals, expecting more approvals in Q1 2026 [20][21] Question: Timing for ACCCESS study data and PMA supplement submission - The 12-month data will be available by the end of June 2026, with submission planned for Q1 2027 [23][25] Question: Cash burn rate and guidance for 2026 - Cash burn is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases [29][30] Question: Competitor's coding strategy and implant numbers - Management indicated plans to pursue dedicated coding for Genio, with no specific implant numbers disclosed but revenue figures suggest a strong sales performance [31][34] Question: Patient demographics for Genio implants - Patients are primarily coming from established referral networks, with many choosing Genio for its minimally invasive design and upgradeable features [59]

Financial Data and Key Metrics Changes - In 2025, net sales were approximately $162 million, a decline from $188.9 million in 2024, primarily due to store closures [20][24] - Gross margin improved by 370 basis points to 26.8% for the full year 2025, compared to 23.1% in 2024 [21] - GAAP net loss decreased to $24 million for the full year 2025, a $25.5 million improvement from a net loss of $49.5 million in 2024 [21] - Adjusted EBITDA improved by $8.5 million, from a loss of $14.5 million in 2024 to a loss of $6 million in 2025 [21][24] Business Line Data and Key Metrics Changes - Proprietary brand sales accounted for 32.8% of cultivation and gardening revenue in 2025, up from 24.2% in 2024 [20] - In the fourth quarter of 2025, proprietary brand sales represented 35.8% of cultivation and gardening revenue, up from 30.4% in the prior year [16] - The storage solutions segment reported net sales of $5.7 million for the fourth quarter of 2025, an increase from $4.5 million in the same period last year [16] Market Data and Key Metrics Changes - The company consolidated 8 retail stores in 2025, reducing its retail footprint to 23 locations as of December 31 [5] - The company is shifting focus from retail to B2B distribution, indicating a strategic pivot in its market approach [59] Company Strategy and Development Direction - The company aims to reach approximately break-even adjusted EBITDA for the full year 2026, focusing on revenue quality rather than volume [5][24] - The company plans to increase proprietary brand sales to 40% of cultivation and gardening revenue by year-end 2026 [24] - The company is expanding into new revenue channels and product extensions, particularly in B2B and home gardening markets [10][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term strategy and the effectiveness of cost reduction initiatives implemented in 2025 [13][27] - The company anticipates modest revenue growth in 2026, with a focus on margin improvement and operational efficiency [24][26] - Management highlighted the importance of proprietary brands as a primary growth driver moving forward [9][15] Other Important Information - The company ended 2025 with $46.1 million in cash and no debt, maintaining a strong balance sheet [23] - A share repurchase program for up to $10 million of the company's outstanding common stock was authorized by the board of directors [13][23] Q&A Session Summary Question: Share repurchase program considerations - Management indicated that the decision to initiate a share repurchase program was based on the current undervaluation of the stock and the lack of suitable acquisition opportunities [31][34] Question: Sales channels for proprietary brands - Currently, about 80% of proprietary brand sales are through GrowGen's own channels, with a goal to diversify towards third-party channels [35][36] Question: Outlook for storage solutions segment - Management noted that the storage solutions segment is experiencing growth and plans to consolidate operations to enhance efficiency [39][41] Question: Future of retail store base - The company plans to continue reducing its retail store count, focusing on B2B operations rather than consumer retail [58][60] Question: Operating expenses outlook - Management expects continued reductions in operating expenses in 2026, benefiting from previous cost-cutting measures and store closures [61][62]

Financial Data and Key Metrics Changes - Relmada closed 2025 with a cash balance of $93 million, an increase from approximately $45 million at the end of 2024, primarily due to a successful $160 million private financing [19][20] - Research and development expenses for Q4 2025 totaled $8.1 million, a decrease from $11 million in Q4 2024, driven by reduced study costs from completed trials [20] - General and administrative expenses increased to $12.3 million in Q4 2025 from $8.1 million in Q4 2024, primarily due to higher compensation costs [21] - The net loss for Q4 2025 was $19.9 million, or $0.27 per share, compared to a net loss of $18.7 million, or $0.62 per share, in Q4 2024 [23] Business Line Data and Key Metrics Changes - The NDV-01 program reported a 12-month complete response rate of 76% in high-risk NMIBC patients, with an 80% response rate in the BCG unresponsive population [11][12] - Sepranolone is preparing for a proof of concept study in Prader-Willi syndrome, with plans to initiate in mid-2026 [18] Market Data and Key Metrics Changes - The U.S. market for intermediate-risk bladder cancer patients is estimated at 70,000-75,000 annually, while the second-line treatment for BCG unresponsive patients is about 5,000 annually [13][15] - Only 35% of intermediate-risk patients currently receive adjuvant therapy, indicating significant market potential for new treatments [53] Company Strategy and Development Direction - The company plans to initiate the phase 3 RESCUE program for NDV-01 in mid-2026, with two registrational pathways focusing on intermediate-risk and BCG unresponsive patients [5][13] - The strategic focus includes enhancing clinical data presentation and establishing a robust supply chain for sepranolone [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical programs and long-term prospects, emphasizing the importance of execution in the upcoming RESCUE program [24][57] - The company aims to redefine the standard of care in bladder cancer with NDV-01, leveraging its unique sustained-release formulation [17] Other Important Information - The company has strengthened its development team with the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Urology [6] - A successful $160 million private financing was completed, providing capital through 2029 [8][20] Q&A Session Summary Question: Will additional data from the phase two study be presented? - Management confirmed that updated 12-month data will be presented at AUA and plans to share data every three months [26][29] Question: How will the company ensure that second-line patients are accurately categorized? - The company will limit prior therapy lines to two and will monitor patient characteristics closely to ensure accurate categorization [27][30] Question: What is the expectation for enrollment cadence across the studies? - Management indicated that the unique in-office profile of NDV-01 could serve as a recruitment advantage, despite a crowded market [34][35] Question: What is the FDA's requirement for follow-up duration before submitting the NDA? - The FDA has not stipulated a minimum follow-up duration but is interested in the totality of the data regarding response and durability [36] Question: How do the complete response rates compare between phase 2 and phase 3? - Management expects to exceed the benchmark of 75% two-year recurrence-free survival based on the statistics structured for the trial [42]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 12% to a record $6.6 million, and for the full year, revenue increased 13% to $22.7 million, another company record [6][22] - Gross margin for Q4 2025 increased to 91.4% compared to 91.1% in Q4 2024, reflecting the strength of the software-driven SaaS model [6][24] - The company achieved annual operating profitability for the first time since going public, with net income of $1.3 million and EPS of $0.06 [7][22] - Adjusted EBITDA for Q4 2025 was a record $1.9 million, and for the full year, it reached $2.6 million, nearly five times the previous year [8][22] Business Line Data and Key Metrics Changes - SaaS revenue for Q4 2025 grew 12% to $6.62 million, representing over 99% of total revenue [24] - The average price per transaction increased by 25% in Q4 2025 compared to the previous year, indicating pricing power for the company's unique product [18] Market Data and Key Metrics Changes - The banking and lending sector continues to grow, with year-over-year growth nearly doubling, while retail saw a decline of 1% [37] - The automotive sector experienced a significant growth of 125% year-over-year, driven by channel partners [68] Company Strategy and Development Direction - The company aims to build a durable, differentiated, high-margin business by expanding with existing customers and onboarding new ones while maintaining disciplined execution [20] - There is a focus on diversifying into new verticals such as title insurance, automotive, specialty finance, background screening, logistics, and digital account security [18][17] - The company is refining its sales team and channel partner program to drive significant growth across various verticals [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, particularly in banking, which is less dependent on interest rates or consumer confidence [18] - The company is well-positioned to capitalize on new opportunities as interest rates change, with expectations of continued revenue growth and improved profitability [35] Other Important Information - The company ended the year with $9.6 million in cash and a strong debt-free balance sheet, reflecting strong cash generation from operations [7][33] - The company has been recognized as a leader in identity verification in financial services by the IDC MarketScape report [17] Q&A Session Summary Question: What was the performance of the bank lending channel in Q4? - The banking and lending sector continues to grow, with nearly double year-over-year growth, while retail was down 13% compared to Q4 2024 [37][39] Question: How does the pipeline look for new customers in 2026? - The pipeline looks strong, driven by the new desktop solution and partnerships, particularly with mid-sized credit unions and banking institutions [40] Question: What is the status of the relationship with Ping Identity? - The company needs to improve its channel partnership with Ping Identity to facilitate better integration and sales [45] Question: What are the growth expectations for 2026? - While the company does not provide formal guidance, there is built-in growth from existing clients, and the focus is on how quickly implementations can occur [60] Question: What metrics can be shared regarding the automotive sector? - Automotive revenue grew 125% year-over-year, with significant potential for further growth through channel partners [68]

electroCore (NasdaqCM:ECOR) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Speaker5Greetings, and welcome to the electroCore fourth quarter and full year 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. Please make sure to mute yourself. Question and answer session will follow the formal presentation. A reminder, this conference call is being recorded. Earlier today, electroCore published results for the fourth quarter and full year ended December 31, 2 ...

Financial Data and Key Metrics Changes - The company achieved record full-year revenue of $3.9 million, a 20% increase compared to 2024, with fourth quarter revenue of $1.5 million, representing a 92% increase over the prior year period [3][9] - Gross profit for the fourth quarter was $1 million, or 69% of revenue, compared to $0.4 million, or 46% of revenue in the prior-year quarter, marking a 188% increase and a 23 percentage point improvement in gross margin [10] - Operating expenses totaled $3.9 million for the fourth quarter, up from $3.5 million in the prior year quarter, while for the full year, operating expenses totaled $15.2 million, compared to $15.5 million in the prior year period [11][12] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by an increase in surgical procedures across both the Catamaran and SImmetry+ platforms, particularly in the second half of 2025, led by new physician users [3][9] - The company hosted 24 physicians in targeted training sessions for both platforms during the fourth quarter, supporting clinical engagement [4] Market Data and Key Metrics Changes - The company received FDA 510(k) clearance for the next generation SImmetry+ SI joint fusion system, enhancing its ability to serve a broader range of surgeon preferences and patient anatomies [4][8] - The company expanded its intellectual property portfolio, receiving notices of allowance for multiple applications expected to issue in 2026, bringing its global estate to 29 issued U.S. patents and 31 pending applications [7] Company Strategy and Development Direction - The company is focused on advancing its market position with increased adoption across its expanding portfolio, leveraging regulatory and market momentum to drive broader commercial uptake [8] - The company aims to optimize its cost structure and scale operations to extend market reach more efficiently, with plans to accelerate revenue growth and deliver sustained value [8][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet and exceed expectations in 2026, citing strong adoption momentum and an engaged pipeline [22][24] - The company believes that its multi-product portfolio will address various physician and patient needs, enhancing its competitive position in the market [30] Other Important Information - The company strengthened its balance sheet through a $2.85 million PIPE financing and a subsequent private placement of senior convertible notes for gross proceeds of $4.3 million, providing additional runway for commercial and clinical priorities [5][12] Q&A Session Summary Question: How representative is the Q4 operating expense rate for 2026? - Management indicated that the Q4 operating expense of $3.9 million is a better baseline moving forward into 2026, with some higher integration costs falling out in Q4 [18][19] Question: What is the revenue outlook for 2026? - Management did not provide specific projections but expressed excitement about adoption momentum and the impact of new product launches on revenue growth [22][24][28] Question: What are the key drivers for revenue growth in 2026? - Management highlighted the multi-product portfolio and the commercial expansion as key drivers for revenue growth, with a focus on addressing various physician needs [30][39]

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for Q4 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The Take Aim Lymphoma study in primary CNS lymphoma is progressing well, with expectations for accelerated submissions in the U.S. and Europe [4] - Initial data from the ongoing AML triplet study showed that 5 of 8 evaluable patients achieved MRD conversion, indicating potential effectiveness of the treatment combination [8][9] Market Data and Key Metrics Changes - The company is focusing on expanding emavusertib studies into additional NHL subtypes, particularly CLL, where current treatments have limitations [5][6] - The company is prioritizing NHL studies over AML due to resource allocation and the potential for registrational approval in PCNSL [14][15] Company Strategy and Development Direction - Curis aims to improve the treatment paradigm for CLL by combining emavusertib with BTKI regimens, targeting deeper responses and potential complete remission [6][39] - The company is actively engaging with clinical sites in the U.S. and Europe to advance its studies and expects to present initial data at the ASH annual meeting in December [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in treatment options for patients with CLL and NHL [4][9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but is confident in its financial position to support operations into the second half of 2027 [12][27] Other Important Information - Curis has secured initial gross proceeds of $20.2 million from financing, which will support its operations and clinical trials [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on PCNSL enrollment? - Management confirmed that enrollment is on track, with expectations for full enrollment within 12-18 months [22] Question: Should revenue modeling reflect no meaningful revenue for 2026? - Management confirmed that there will be no meaningful revenue, as cash flows from Erivedge have ended [27][28] Question: What data should be expected at ASH 2026 for CLL? - Management stated that they hope to present meaningful data regarding the treatment's effectiveness, focusing on deepening patient responses [35][36]

Financial Data and Key Metrics Changes - In Q3 2026, revenues were $329.1 million, down from $335.4 million in the prior year, reflecting a decrease of approximately 1% [20] - Adjusted operating loss was $24.3 million compared to $20.9 million in the prior year, while adjusted EBITDA was approximately break-even compared to $6 million in the prior year [20][21] - Net loss increased to $3.5 million from $1.3 million in the prior year, with adjusted loss per diluted share rising to $0.15 from $0.05 [21] Business Line Data and Key Metrics Changes - Children's Book Publishing and Distribution revenues decreased 3% to $197.6 million, with adjusted operating profit improving to $8.9 million from $7.6 million [21] - Book Fairs revenue increased 2% to $113.3 million, driven by higher revenue per fair, while Book Clubs revenues were relatively flat at $14.6 million [22] - Trade Publishing revenues fell 10% to $69.7 million, impacted by the timing of major releases compared to the prior year [22] Market Data and Key Metrics Changes - International segment revenues were $58.7 million, down from $59.3 million a year ago, with a decline attributed to publication timing [25] - The Australian and UK markets showed strong contributions, benefiting from operational improvements [18] Company Strategy and Development Direction - The company completed a sale leaseback transaction generating over $400 million in net proceeds, aimed at optimizing the balance sheet and enhancing shareholder value [4][19] - A new $300 million share repurchase authorization was announced, including a $200 million modified Dutch auction tender offer [5][29] - The company aims to stabilize its education segment and return to growth in fiscal 2027, focusing on aligning products with district and school needs [15][17] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed fiscal 2026 adjusted EBITDA guidance of $146 million to $156 million, despite the impact of the sale leaseback transactions [31] - The company expects a return to profitability in Q4, driven by improved performance in Book Fairs and Education segments [32] - Management expressed confidence in achieving revenue growth in the fourth quarter, particularly from Book Fairs, while acknowledging challenges in the Trade segment due to prior year comparisons [36][38] Other Important Information - The company established long-term net leverage targets of 2-2.5 times Adjusted EBITDA, balancing growth investments with shareholder returns [28] - Free cash flow in Q3 was $407 million, reflecting proceeds from the sale leaseback transactions [27] Q&A Session Summary Question: Confidence in achieving 2% growth in Q4 - Management highlighted Book Fairs as a major growth factor, with positive initial indications for the quarter [36][37] Question: Sales pipeline for education solutions - Management expects strong performance in summer reading and other educational products, with improving sales pipeline trends [40][43] Question: Adjusted EBITDA guidance for Q4 - Management expressed confidence in achieving the guidance due to cost mitigation actions and the seasonal nature of the business [45][47] Question: Performance of the entertainment segment - Management noted an increase in green lighting activity and anticipated steady growth in the entertainment segment [48][49]